| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Fidaxomicin |
| Brand | Dificlir® |
| Indication | For the treatment of CDI also known as CDAD in adult patients. Rapid Review |
| Assessment Process | |
| Rapid review commissioned | 09/03/2012 |
| Rapid review completed | 23/03/2012 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended. |
| Full pharmacoeconomic assessment commissioned by HSE | 05/12/2012 |
| NCPE assessment completed | 05/02/2013 |
| NCPE assessment outcome | Reimbursement recommended. |
Fidaxomicin (Dificlir®) may be considered a cost-effective use of resources. It should be prescribed according to the recommendations outlined in the recently updated National Clostridium difficile Guidelines (due to be completed in February 2013 www.hpsc.ie).
